Latest News
From the Journals
Spirometry predicts mortality in type 2 diabetes
PRISm occurs in approximately 10% of the general population and has been identified as a predictor of adverse health outcomes.
Latest News
A decade after first DAA, only one in three are HCV free
Patients face barriers to being cured at every step of the way, from being diagnosed to accessing breakthrough DAA agents.
Latest News
Hearing loss tied to more fatigue in middle and older age
Each 10 dB of audiometric hearing loss was associated with a higher likelihood of reporting fatigue nearly every day.
From the Journals
Liver disease gets new name and diagnostic criteria
Formerly known as nonalcoholic fatty liver disease, the condition will now be known as metabolic dysfunction–associated steatotic liver disease (...
Conference Coverage
Does private equity ensure survival of GI practices?
Private equity offers the allure of financial and administrative stability.
Latest News
Evidence weighed for suicide/self-harm with obesity drugs
“It is not yet clear whether the reported cases are linked to the medicines themselves or to the patients’ underlying conditions or other factors...
Latest News
Link between low co-pays for new diabetes drugs and patient adherence
Low co-pays linked with substantially better 12-month adherence to expensive SGLT2 inhibitors and GLP-1 agonists in U.S. patients with type 2...
News
FDA approves cognitive-behavioral app for adults with type 2 diabetes
The app will be available to patients exclusively by prescription, with a planned 90-day use duration.
Conference Coverage
Aging and type 1 diabetes: ‘Complete picture’ 40 years on
“The EDIC study is now shifting its focus during the next 5 years to understand the clinical course of type 1 diabetes in the setting of advancing...
Latest News
Finding mild cognitive impairment quickly in primary care
When it comes to treatment, deprescribing is a priority, as many drug interactions contribute to cognitive disorders.
Latest News
Oral IL-23 receptor antagonist for psoriasis promising: Phase 2b study
Similar to the primary outcome of PASI 75, all treatment groups demonstrated a statistically significant dose-response in PASI 90, compared with...